Form 4: Monte Rosa COO Executes Stock Option Exercise and Sale

Chief Operating Officer Jennifer Champoux exercised 2,175 stock options and subsequently sold the shares under a Rule 10b5-1 plan.

Summary

• Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, Inc., exercised 2,175 stock options at a strike price of $3.98.
• Following the exercise, the reporting person sold the 2,175 shares at a price of $20.00 per share.
• The transactions were executed on May 27, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2026.
• Post-transaction, the reporting person maintains direct beneficial ownership of 62,371 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned insider transaction that does not signal a change in company fundamentals or executive sentiment.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
• The exercise price of $3.98 compared to the sale price of $20.00 reflects significant value appreciation for the executive's equity holdings.

Negatives

• The transaction results in a reduction of the executive's direct equity stake in the company.

Risks

• Continued reliance on Rule 10b5-1 plans is subject to regulatory scrutiny and potential changes in SEC guidelines regarding affirmative defense conditions.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector, often used by executives to diversify personal wealth while maintaining significant long-term alignment with company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among C-suite executives in the NASDAQ-listed biotech industry to avoid allegations of insider trading.
• The volume of shares sold (2,175) is relatively minor compared to the total holdings (62,371), suggesting a standard liquidity event rather than a lack of confidence in the company.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Monte Rosa Therapeutics, GLUE, Insider Trading, Form 4, Stock Options, Biotech